Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Move Sparks Industry Worry Over Wider Price Controls

This article was originally published in PharmAsia News

Executive Summary

A week after India’s drug pricing watchdog slashed the prices of 108 formulations in the diabetes and cardiovascular areas, a debate has kicked off in which the industry is unequivocally questioning the government step to tweak policy while health experts are supporting the move. The government is pointing to a case of “severe market failure” but the industry says the price controls may in fact jeopardize the availability of drugs to patients.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts